Posted 23 February 2021
The TGA's recent decision to put the feelers out on the repurposing of medicines has sparked warnings it could "unravel the pharma industry in Australia" according to legal experts.
Three options have been put forward by the TGA to encourage pharma companies, industry bodies and patient groups to seek registration of new indications but each could result in significant legal, commercial and economic consequences for industry, according to specialist law firm, Pearce IP.